EWTX

Edgewise Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website edgewisetx.com
Employees(FY) 80
ISIN US28036F1057

Performance

+9.34%

-2.32%

+4.34%

+90.23%

+181.35%

YTD

+261.69%

Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Advanced Technical Analysis

Technical Analysis of EWTX 2024-12-20

The stock's indicators reflect a neutral sentiment, with the Moving Average Score at 56 indicating a slight bullish bias, while the Oscillators Score remains neutral at 50, and the overall Technical Score at 53 suggests a cautious outlook. This combination implies that while there is some upward potential, the market lacks strong momentum, warra...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of EWTX

Stock Rank

Recent News & Updates

2024-12-18 09:23
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains(Zacks)
2024-12-17 09:18
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study(Zacks)
2024-12-16 11:56
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease(Benzinga)
2024-12-16 09:13
Sector Update: Health Care Stocks Mixed Pre-Bell Monday(MT Newswires)
2024-12-16 08:42
Sector Update: Health Care(MT Newswires)
2024-12-16 07:55
Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell(MT Newswires)
2024-12-16 07:02
Edgewise weighs fast approval path for muscular dystrophy drug(BioPharma Dive)
2024-12-16 06:00
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)(Business Wire)
2024-12-15 17:00
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)(Businesswire)
2024-12-05 15:25
Edgewise Therapeutics Clarifies FDA Warning Unrelated to Clinical Trials, Data(MT Newswires)
2024-12-05 14:32
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research(Business Wire)
2024-12-05 01:32
Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research(Businesswire)
2024-11-27 07:33
Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating(MT Newswires)
2024-11-26 06:00
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024(Business Wire)
2024-11-25 17:00
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024(Businesswire)
2024-11-08 09:57
RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating(MT Newswires)
2024-11-07 08:00
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Business Wire)
2024-11-06 19:00
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Businesswire)
2024-10-07 17:37
Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now(Insider Monkey)
2024-10-01 08:00
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society(Business Wire)
2024-09-30 20:00
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society(Businesswire)
2024-09-20 07:28
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data(BioPharma Dive)
2024-09-20 06:26
RBC Raises Price Target on Edgewise Therapeutics to $42 From $32, Keeps Outperform, Speculative Risk(MT Newswires)
2024-09-20 05:05
Company News for Sep 20, 2024(Zacks)
2024-09-20 04:52
Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials(Clinical Trials Arena)
2024-09-19 16:08
How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease(Investor's Business Daily)
2024-09-19 14:51
Leerink Partners Raises Edgewise Therapeutics' Price Target to $42 From $32, Outperform Rating Maintained(MT Newswires)
2024-09-19 13:51
Top Midday Gainers(MT Newswires)
2024-09-19 12:55
Why Edgewise Therapeutics Stock Is Up 50% on Thursday(Motley Fool)
2024-09-19 12:31
Wedbush Adjusts Edgewise Therapeutics Price Target to $44 From $31, Maintains Outperform Rating(MT Newswires)

Page 1 of 7

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.